NCT01412515 2026-06-04A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's SarcomaInstitut National de la Santé Et de la Recherche Médicale, FrancePhase 2 Terminated11 enrolled